Mechanisms of CBD for Chronic Pain

Last updated: April 9, 2025
Sponsor: University of Utah
Overall Status: Completed

Phase

1

Condition

Chronic Pain

Pain

Treatment

Cannabidiol

Placebo

Clinical Study ID

NCT04044729
IRB_00124865
  • Ages 18-50
  • All Genders

Study Summary

This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 18-50 yrs.

  • Chronic musculoskeletal and joint pain for at least 3 months or longer.

  • Participants must live within a 60 mile radius of Salt Lake City, Utah to beeligible.

Exclusion

Exclusion Criteria:

  • Current or past neurological illness.

  • Substance abuse or dependence within the prior 90 days.

  • Contraindication to brain MRI.

  • Type I and type II diabetes.

  • Unstable medical conditions.

  • Consumption of more than 2 drinks of alcohol per night.

  • Current pregnancy or planning to become pregnant or breastfeeding.

  • History of seizures or head trauma at PI discretion.

  • Active or history of major mental illness

  • Use of opioid medications in the past 30 days.

  • LFT results 3 times greater than the upper limit of normal at the screening.

  • Participants may be excluded if the PI feels they do not meet safety criteria.

Study Design

Total Participants: 24
Treatment Group(s): 2
Primary Treatment: Cannabidiol
Phase: 1
Study Start date:
March 16, 2020
Estimated Completion Date:
December 01, 2024

Study Description

The aim of this trial is to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain. Participants will include individuals with chronic pain, who will be randomized into one of two intervention conditions: low THC/high CBD or placebo. In addition to receiving CBD or placebo, participants also will complete symptom assessments of chronic pain data (intensity, quality, interference/disability) throughout the study. These measures will be gathered prior to and following the fifth doses (dosing will occur once per day for five days) of CBD or placebo. A secondary objective will be to examine the association between clinical and inflammatory markers.

Connect with a study center

  • University Of Utah

    Salt Lake City, Utah 84108
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.